Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 9/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12845155 | 0.80 | LIPG (0.53) | P2RX7LPLLIPGF11 | |
| SCHEMBL20068614 | 0.79 | DGAT1 (0.56) | DGAT1LPLLIPGF11 | |
| SCHEMBL22448166 | 0.79 | LIPG (0.51) | P2RX7LPLLIPGF11 | |
| SCHEMBL17787540 | 0.77 | DGAT1 (0.43) | DGAT1P2RX7LPLLIPG | |
| SCHEMBL18015695 | 0.77 | DGAT1 (0.44) | DGAT1LPLLIPGF11 | |
| SCHEMBL21202836 | 0.75 | P2RX7 (0.39) | DGAT1P2RX7LPLLIPGF11 | |
| SCHEMBL22448147 | 0.75 | LIPG (0.54) | P2RX7LPLLIPGMAPK1F11 | |
| SCHEMBL21202800 | 0.75 | DGAT1 (0.43) | DGAT1LPLLIPG | |
| SCHEMBL21125909 | 0.75 | DGAT1 (0.67) | DGAT1LPLLIPG | |
| SCHEMBL23211089 | 0.73 | DGAT1 (0.40) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| WO-2016124304-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | DGAT1 1835/4885TDP1 2457/4885P2RX7 1254/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | DGAT1 1328/4885TDP1 3214/4885P2RX7 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.